Lhasa Limited shared knowledge shared progress
Publications

Development of an Adverse Outcome Pathway (AOP) Network for Carcinogenicity Using Expert-Derived (Q)SAR Knowledge. Poster

pdf fileStalford SA; Cayley A; Foster R; Kane S; Williams RV;

The prediction of carcinogenicity and related toxicity endpoints has always been a principal research area for in silico (Q)SAR systems and, as a result, software relating to these endpoints is well developed. In recent years, predictions provided by these systems have become embedded in regulatory guidance, where they may be used to replace or augment other testing methods. Consequently, it is important that the predictions are as accurate as possible and are provided in such a way that they can be easily integrated with other sources of evidence. For example, suggested revisions to the ICH S1 guidance are under consideration which would negate the need to conduct a two year rodent carcinogenicity assay if there is knowledge of pharmacologic targets and pathways, alongside toxicological and other data, which could provide sufficient information to anticipate the outcome of a carcinogenicity bioassay. This review highlights the work undertaken so far to rearrange knowledge contained within Derek Nexus into an AOP network for carcinogenicity. This will allow for 1) easier interpretation of the evidence available that relates to a prediction, 2) integration of existing and emerging in vitro and in vivo assays, and 3) expansion of the scope of predictions which can be made for this endpoint.

Download

© 2019 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.